TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02220985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04713319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panavital
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
Study: NCT04745442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin + best available treatment
Description: The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available treatment
Description: The subject will be treated with the best available treatment for COVID-19.
Study: NCT05842980

Intervention type: OTHER
Intervention: sepsis
Description: collect 5ml blood from patient
Study: NCT05331833

Intervention type: RADIATION
Intervention: The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
Study: NCT02048293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Laboratorios Chalver de Colombia S.A.
Description: Anesthetic induction for orotracheal intubation. Group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Laboratorios Chalver de Colombia S.A.
Description: Anesthetic induction for orotracheal intubation. Group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fada Remifentanilo
Description: Anesthetic induction for orotracheal intubation. Group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fada Remifentanilo
Description: Anesthetic induction for orotracheal intubation. Group B
Study: NCT00686998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Oral Suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: PO BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02914587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTAS System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Implantation
Study: NCT01603238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LC15-0444
Description: A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
Study: NCT06537778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 21 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
Study: NCT00207636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Decision making tool
Description: The intervention consisted of access to a computer tailored decision aid designed to promote informed decision making.
Study: NCT03986034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: During Venetoclax
Description: Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
Study: NCT03540017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
Study: NCT04219371

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT01776268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral priming
Description: Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
Study: NCT04285723

Intervention type: OTHER
Intervention: alpelisib
Description: Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
Study: NCT01859351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-554
Study: NCT01940718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Androgel
Description: T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
Study: NCT02218203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
Study: NCT03498638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Therapy
Description: Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
Study: NCT02220985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03065738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tibial reduction osteotomy in total knee replacement
Description: reduction osteotomy :downsizing of tibial tray with lateralization
Study: NCT05436912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study: NCT02220985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV and PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with CD45RA-depleted cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with CD45RA-depleted cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with CD45RA-depleted cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT with CD45RA-depleted cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT02218203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan
Study: NCT02220985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT02218203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine
Study: NCT00735423

Intervention type: DEVICE
Intervention: No intervention
Description: IDE used for outcome measurement not intervention
Study: NCT01573468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally once on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
Study: NCT02220985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT04614155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Take part in health education session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Receive HPV self-collection kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03847688

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
Study: NCT04375943

Intervention type: DRUG
Intervention: Antidiabetic
Description: Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy

Intervention type: DRUG
Intervention: Antidiabetic
Description: Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Study: NCT02695472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 Milligrams NSI-189
Description: Orally Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 Milligrams NSI-189
Description: Orally Administered
Study: NCT02632864

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton arm
Description: Proton beam therapy
Study: NCT03874143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention for Quality of Care
Description: Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
Study: NCT03964935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline HCl 1mg Oral Powder
Description: Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Used to irrigate periodontal pockets after SRP
Study: NCT04345653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate (HCQ)
Description: Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
Study: NCT02856308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hairstetics hair implant device
Study: NCT01449981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Twelve-Step Facilitation
Description: The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
Study: NCT02061553

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivation
Description: Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intention
Description: Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-Tech
Description: Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
Study: NCT04481958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-PROTECT
Description: The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
Study: NCT04509167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptides
Description: Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
Study: NCT00418938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Either 5mg/kg OR 10mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m\^2 IV (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m\^2 IV (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m\^2 IV (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m\^2 IV (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects